Clinical trials: High-risk Localized Prostate Cancer
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Radiation Therapy
Adjuvant Chemotherapy for High Malignant Prostate Cancer
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer.
- Conditions
- Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
- Trial name
- PKUFH-GS5 (NCT06864533)
- Testing
- Docetaxel
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Peking University First Hospital
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Prostate Cancer
Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer
Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.
- Trial name
- NCT03526510
- Testing
- Conventionally Fractionated versus Hypofractionated Boost
- Where
- Canada
- Volunteers
- 178 people
- Sponsor
- Dr. Patrick Cheung
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
This clinical trial evaluates the effectiveness of focal ablation with either focal cryotherapy or high intensity frequency ultrasound for the treatment of men with localized prostate cancer.
- Conditions
- Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT06178354
- Testing
- Cryosurgery, High-Intensity Focused Ultrasound Ablation, Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Davis
Prostate Cancer
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in…
- Trial name
- NCT00924469
- Testing
- Abiraterone, Leuprolide, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, HDR
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
- Trial name
- NCT04645810
- Testing
- High-Dose-Rate Brachytherapy
- Where
- United States
- Sponsor
- University of Rochester
High Risk Localised Prostate Carcinoma
Neo-adjuvant Abiraterone Prostate Study
The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy.
- Trial name
- NCT02160353
- Testing
- Abiraterone acetate, Prednisolone
- Where
- 3 sites in Ireland
- Volunteers
- 45 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada
This is an investigational study on the use of high intensity focused ultrasound (HIFU) in the management of localized prostate cancer (T1c/T2a) as a primary non-comparative study.
- Trial name
- NCT00573586
- Testing
- Sonablate 500 (SB-500)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- SonaCare Medical
Prostate Adenocarcinoma
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
This study is a prospective, open label, single arm phase II trial. A total of 22 patients will be treated with atezolizumab, PROSTVAC, and pre-operative MVA-BN-Brachyury to confirm the efficacy of prostatic combination…
- Trial name
- AtezoVax (NCT04020094)
- Testing
- MVA-BN-Brachyury
- Where
- United States
- Sponsor
- University of Utah
Prostate Cancer
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
- Trial name
- ProAMFocal (NCT06491056)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects…
- Trial name
- NCT07335796
- Testing
- BMS-986165, Degarelix
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Risk Localized Prostate Cancer, Synchronous Metastatic Hormone-Sensitive Prostate Cancer
Prospective Prostate Cancer Infrastructure
The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer.
- Trial name
- ProPCI (NCT07560748)
- Where
- Netherlands
- Volunteers
- 700 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Registry for Prostate Cancer Focal Therapy
Whole gland therapy (radical prostatectomy and radiotherapy) has been the conventional treatment for localized prostate cancer, but randomized controlled trials have not demonstrated survival benefits compared with watchful…
- Trial name
- NCT07792590
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Prostate Cancer
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with…
- Trial name
- NCT06220435
- Testing
- Ultra-hypofractionated radiotherapy regimen.
- Where
- 2 sites in Sweden
- Volunteers
- 76 people
- Sponsor
- Region Skane
Prostate Carcinoma
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy.
- Trial name
- NCT02960087
- Testing
- Low dose rate brachytherapy, High dose rate brachytherapy
- Where
- 7 sites in Canada
- Volunteers
- 334 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer
Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer
The aim of the focal treatment HIFU is to destroy the cancer without causing side effects in contrast to radical treatments. Radical treatments (surgery or radiation therapy) are the standard therapies for patient with…
- Trial name
- FOCALE (NCT03568188)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 174 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca